# Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

> **NCT01740063** · PHASE2 · COMPLETED · sponsor: **Ansun Biopharma, Inc.** · enrollment: 423 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** DAS181-F02 formulation
- **DRUG:** DAS181-F04 formulation
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01740063
- **Lead sponsor:** Ansun Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2019-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740063, "Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01740063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*